In Issue 10 of Malignant Haematology Research Review:

  • Venetoclax or placebo in combination with bortezomib
    and dexamethasone in relapsed or refractory multiple
    myeloma (BELLINI)
  • Belantamab mafodotin plus bortezomib and
    dexamethasone in patients with relapsed or
    refractory multiple myeloma (DREAMM-7)
  • Isatuximab, carfilzomib, lenalidomide,
    and dexamethasone induction in newly
    diagnosed myeloma

Malignant_Haematology_Research_Review_Issue_10